A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

NCT02297425 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC

Interventions

DRUG: PF-06459988

Sponsor

Pfizer